Comparable stake leader
Carlson Capital, L.P.
SEC ownership of TFF Pharmaceuticals, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001733413.
Disclosed value leader
Carlson Capital, L.P.
Comparable rows
0/15
Latest evidence
03 Jul 2024
- Parsed ownership sources
- 3/4/5
- Largest SEC-reported holder
- Carlson Capital, L.P.
- Latest parsed ownership date
- 03 Jul 2024
- Issuer CIK
- 0001733413
- Issuer location
- Austin, TX
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of TFF Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Carlson Capital, L.P.
Disclosed value leader
Carlson Capital, L.P.
Comparable rows
0/15
Latest evidence
03 Jul 2024
3/4/5
Highest disclosed value: $4,198,493
15 rows are not safely comparable across share classes.
Showing 1-8 of 15 holder rows.
Quick read
Carlson Capital, L.P. has the largest disclosed position value at $4.2M.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Carlson Capital, L.P.'s linked filing trail.
Disclosed position value
Top 5
Carlson Capital, L.P.
$4.2M
Malcolm P. Fairbairn
$519.9K
Harlan F. Weisman
$347.4K
Zamaneh Mikhak
$61K
Robert S. Mills
$25K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-8 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Carlson Capital, L.P. |
3/4/5
10%+ Owner
|
—
mixed-class rows
|
$4,198,493
10,129,000 shares
mixed-class rows
|
— | 15 Aug 2023 |
| Malcolm P. Fairbairn |
3/4/5
Director
|
—
class O/S missing
|
$519,876
1,327,568 shares
|
— | 19 May 2021 |
| Harlan F. Weisman |
3/4/5
President and CEO, Director
|
—
mixed-class rows
|
$347,373
914,542 shares
mixed-class rows
|
— | 03 Jul 2024 |
| Zamaneh Mikhak |
3/4/5
Chief Medical Officer
|
—
mixed-class rows
|
$61,005
165,968 shares
mixed-class rows
|
— | 03 Jul 2024 |
| Robert S. Mills |
3/4/5
Director
|
—
mixed-class rows
|
$24,989
66,977 shares
mixed-class rows
|
— | 03 Jul 2024 |
| Kirk Allen Coleman |
3/4/5
Chief Financial Officer
|
—
mixed-class rows
|
$22,109
66,643 shares
mixed-class rows
|
— | 03 Jul 2024 |
| Stephen Rocamboli |
3/4/5
Director
|
—
mixed-class rows
|
$17,165
46,997 shares
mixed-class rows
|
— | 03 Jul 2024 |
| Glenn R. Mattes |
3/4/5
President and CEO, Director
|
—
class O/S missing
|
$16,839
43,000 shares
|
— | 16 May 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 09 Jun 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-15 of 15 reporting-owner rows connected to TFF Pharmaceuticals, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
15
Largest Forms 3/4/5 holder
Carlson Capital, L.P.
Net 12M change
$0
Latest report
03 Jul 2024
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Carlson Capital, L.P. | 10%+ Owner | $4,198,493 | Filing P/S | 15 Aug 2023 | ||
| Malcolm P. Fairbairn | Director | $519,876 | Mixed | 19 May 2021 | ||
| Harlan F. Weisman | President and CEO, Director | $347,373 | Mixed | 03 Jul 2024 | ||
| Zamaneh Mikhak | Chief Medical Officer | $61,005 | Mixed | 03 Jul 2024 | ||
| Robert S. Mills | Director | $24,989 | Mixed | 03 Jul 2024 | ||
| Kirk Allen Coleman | Chief Financial Officer | $22,109 | Mixed | 03 Jul 2024 | ||
| Stephen Rocamboli | Director | $17,165 | Mixed | 03 Jul 2024 | ||
| Glenn R. Mattes | President and CEO, Director | $16,839 | Mixed | 16 May 2022 | ||
| Brandi Roberts | Director | $11,159 | Mixed | 03 Jul 2024 | ||
| Catherine C. Lee | Director | $2,013 | Mixed | 03 Jul 2024 | ||
| Thomas B. King | Director | $1,838 | Mixed | 03 Jul 2024 | ||
| Michael A. Patane | Director | $1,393 | Mixed | 18 Apr 2024 | ||
| Christopher Cano | Chief Operating Officer | Mixed | 22 Sep 2021 | |||
| Randy H. Thurman | Director | Mixed | 29 Sep 2022 | |||
| Aaron G.l. Fletcher | Director | Mixed | 29 Dec 2022 |
Recent insider transactions for TFF Pharmaceuticals, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.